Table I.

Therapeutic compounds changing mutant p53 conformation to wild-type-like structure that are under evaluation in clinical trials.

Agent	Target	Class	Mechanism	Phases of clinical trials	Clinical trial nos.
APR-246	p53 R175H p53 R273H	Small molecule	Wild-type-like conformation of p53 by binding to thiol groups	I-III	NCT03072043, NCT03588078, NCT03745716, NCT04383938, NCT04419389, NCT03931291, NCT04214860
PEITC	R175H P223L	Phytochemical	Wild-type-like conformation of p53, oxidative stress	I-II	NCT01790204, NCT03034603
PC14586	Y220C	Small molecule	Selectively restores wild-type p53 conformation	I	NCT04585750
ATO	R175H V272M R282W E285K Y234C	Small molecule	Restores wild-type p53 conformation	I-II	NCT03855371, NCT04489706, NCT04695223, NCT04869475
Sodium stibogluconate	65 mutants	Pentavalent antimony compound	Restores wild-type p53 conformation	II	NCT04906031
COTI2	R175H R273H R273C R282W	Zn2+ chelator	Inhibition of mutant p53 misfolding	I	NCT02433626